- Home
- PGRE vs SAVA Comparison
PGRE vs SAVA Comparison
Compare PGRE & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- SAVA
- Stock Information
- Founded
- PGRE 1978
- SAVA 1998
- Country
- PGRE United States
- SAVA United States
- Employees
- PGRE N/A
- SAVA N/A
- Industry
- PGRE Real Estate Investment Trusts
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- SAVA Health Care
- Exchange
- PGRE Nasdaq
- SAVA Nasdaq
- Market Cap
- PGRE 1.1B
- SAVA 1.3B
- IPO Year
- PGRE 2014
- SAVA N/A
- Fundamental
- Price
- PGRE $4.71
- SAVA $32.18
- Analyst Decision
- PGRE Hold
- SAVA Strong Buy
- Analyst Count
- PGRE 3
- SAVA 3
- Target Price
- PGRE $4.50
- SAVA $111.50
- AVG Volume (30 Days)
- PGRE 970.4K
- SAVA 1.6M
- Earning Date
- PGRE 10-30-2024
- SAVA 11-07-2024
- Dividend Yield
- PGRE 2.97%
- SAVA N/A
- EPS Growth
- PGRE N/A
- SAVA N/A
- EPS
- PGRE N/A
- SAVA N/A
- Revenue
- PGRE $553,641,000.00
- SAVA N/A
- Revenue This Year
- PGRE N/A
- SAVA N/A
- Revenue Next Year
- PGRE N/A
- SAVA N/A
- P/E Ratio
- PGRE N/A
- SAVA N/A
- Revenue Growth
- PGRE N/A
- SAVA N/A
- 52 Week Low
- PGRE $4.21
- SAVA $8.79
- 52 Week High
- PGRE $5.92
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- PGRE 36.77
- SAVA 64.80
- Support Level
- PGRE $4.66
- SAVA $25.72
- Resistance Level
- PGRE $5.35
- SAVA $29.49
- Average True Range (ATR)
- PGRE 0.15
- SAVA 2.63
- MACD
- PGRE -0.05
- SAVA 0.48
- Stochastic Oscillator
- PGRE 7.91
- SAVA 82.89
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. Paramount Group derives nearly all of its revenue in the form of rental income from leasing its offices to tenants.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.